Fairvalue-Calculator Fairvalue-Calculator
EN DE

HighTide Therapeutics, Inc (HTTIF) Fair Value & Analysis

Healthcare · US · Market cap $178M

Price$0.3499
Fair Value$0.2700
Upside-22.8%
Quality76/100
Evidence: Low Range $0.2000 – $0.3300

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

HighTide Therapeutics, Inc (HTTIF) currently trades at $0.3499, while our model-based Fair Value estimate is $0.2700 — implying the stock looks roughly 22.8% overvalued today. We read business quality at 76/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase I clinical trial to treat gradual loss of kidney function over time; phase IIb for the treatment of pathogenetic complexity and heterogeneity; phase I to treat obesity; and phase II for the treatment of chronic cholestatic liver disease. The company is also developing HTD4010, a polypeptide drug, which is in phase I clinical trial for the treatment of alcoholic hepatitis; HTF1037 a preclinical-stage for the treatment of obesity and comorbidities; HTF1057 a preclinical-stage a drug candidate for the treatment of neurodegenerative diseases; HTD1804 that is in preclinical trial to treat obesity; and HTD1805, a multifunctional small molecule drug, which is in preclinical trial…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is HighTide Therapeutics, Inc (HTTIF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.2700 versus a price of $0.3499 — about −23% (overvalued). Model-based estimate, not financial advice.
What is the fair value of HTTIF?
Our 21-model fair value for HighTide Therapeutics, Inc is $0.2700 (as of Jun 24, 2026), built from audited fundamentals. The current price is $0.3499.
What is the quality score of HTTIF?
HighTide Therapeutics, Inc has a Quality Score of 76/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.